Adenomyosis: What is New?

Levent M Senturk, Levent M. Şentürk, Metehan Imamoglu, Metehan İmamoğlu
Women's health (London, England) · 2015 · vol. 11(5) , pp. 717–724 · doi:10.2217/whe.15.60 · W2145422360
review OA: gold CC0 ⤵ 29 in-corpus citations
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This review discusses the etiopathogenesis, diagnosis, clinical findings, and treatment options for adenomyosis, a condition involving endometrial tissue invading the myometrium.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Adenomyosis is described as the benign invasion of endometrium into the myometrium, with endometrial glands and stroma surrounded by the hypertrophic and hyperplastic myometrium. It may affect 20% of female population and most widely seen among perimenopausal and multiparous women. Its etiopathogenesis, diagnosis, clinical findings and current various treatment options will be discussed in this article.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Endometrium Perimenopause Adenomyosis Adenomyosis Adenomyosis Contraceptive Agents, Female Contraceptive Agents, Female Drug Implants Endometrium Female Humans Intrauterine Devices, Medicated Menorrhagia Menorrhagia Menorrhagia Menorrhagia Risk Factors Women's Health

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (64)

Cited by (29)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:17:39.907309+00:00
License: CC0 · commercial use OK